Dynamics of onychodystrophy manifestations in patients with torpid psoriasis treated with an interleukin-17 blocker

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Background: Psoriasis in children, especially with nail plate involvement and juvenile psoriatic arthritis, is a complex clinical problem for which there is a lack of data on the safety and efficacy of newer systemic therapies. Therefore, it is necessary to present clinical observations using modern medications.

Description of the clinical cases: Two clinical observations of children aged 12 and 11 years with progressive vulgar psoriasis complicated by nail involvement are presented. One patient was diagnosed with juvenile psoriatic arthritis. In both cases, traditional treatment approaches (topical agents, phototherapy, methotrexate) were insufficiently effective or were associated with adverse effects. Use of secukinumab according to approved treatment regimens resulted in significant clinical remission of skin and nail lesions by weeks 16–24, with a reduction in PASI scores to 0 and NAPSI to 0, as well as an improvement in quality of life and the absence of serious adverse effects. Pre-therapy assessments included serological and radiographic tests, as well as consultations with specialized specialists to confirm the absence of contraindications.

Conclusion: These clinical cases demonstrate the high efficacy and safety of secukinumab in children with severe psoriasis and nail lesions. This confirms the feasibility of using this biologic agent in pediatric patients who have failed traditional treatments and who need to improve their quality of life.

About the authors

A. A. Khotko

Clinical Dermatovenereology Dispensary; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation

Email: chernenko_ea@mail.ru
ORCID iD: 0000-0002-8688-4876

Dr. Sci. (Med.), Dermatovenereologist, Deputy Chief Physician for Medical Affairs; Associate Professor, Department of Dermatovenereology and Cosmetology

Russian Federation, Krasnodar; Moscow

E. A. Inyukhina

Clinical Dermatovenereology Dispensary

Author for correspondence.
Email: chernenko_ea@mail.ru
ORCID iD: 0000-0003-0919-1184
SPIN-code: 7616-5864

Dermatovenereologist, Head of Dermatology Department No. 1

Russian Federation, Krasnodar

Ya. V. Kozyr

Clinical Dermatovenereology Dispensary

Email: chernenko_ea@mail.ru
ORCID iD: 0000-0001-9880-0417

Dermatovenerologist, Department of Paid Medical Services

Russian Federation, Krasnodar

References

  1. Бакулев А.Л., Тальникова Е.Е. Псориаз в педиатрической практике. Вопросы современной педиатрии. 2020;19(6):496–9. [Bakulev A.L., Talnikova E.E. Psoriasis in pediatric practice. Voprosy sovremennoy pediatrii. 2020;19(6):496–9. (In Russ.)].
  2. Akimichi Morita, Hidehisa Saeki. Pediatric psoriasis: Understanding pathological conditions and advances in treatment. J Dermatol. 2024;51:185–95. https://dx.doi.org/10.1111/1346-8138.17049
  3. Augustin M., Glaeske G., Radtke M.A., et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–6. https://dx.doi.org/10.1111/j.1365-2133.2009.09593.x
  4. Мурашкин Н.Н., Глузмин М.И., Хотко А.А. и др. Факторы риска возникновения псориаза у детей, возрастные особенности клиники и течения заболевания. Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2010;5(12):30–5. [Murashkin N.N., Gluzmin M.I., Khotko A.A., et al. Risk factors for the development of psoriasis in children, age-related clinical features and the course of the disease. Sovremennyye problemy dermatovenerologii, immunologii i vrachebnoy kosmetologii. 2010;5(12):30–5. (In Russ.)].
  5. Relvas M., Torres T. Pediatric Psoriasis. Am J Clin Dermatol. 2017;18:797–811. https://dx.doi.org/10.1007/s40257-017-0294-9
  6. Brunello F., Tirelli F., Pegoraro L., et al. New Insights on Juvenile Psoriatic Arthritis. Front Pediatr. 2022;10:884727. https://dx.doi.org/10.3389/fped.2022.884727
  7. Мурашкин Н.Н., Материкин А.И., Амбарчян Э.Т. и др. Псориаз и псориатический артрит в детском возрасте. Вопросы современной педиатрии. 2020;19(6):444–51. [Murashkin N.N., Materikin A.I., Ambarchyan E.T., et al. Psoriasis and psoriatic arthritis in childhood. Voprosy sovremennoy pediatrii. 2020;19(6):444–51. (In Russ.)].
  8. Губарь Е.Е., Корсакова Ю.Л., Логинова Е.Ю. и др. Поражение ногтей при псориатическом артрите. Данные общероссийского регистра. Научно-практическая ревматология. 2021;59(5);563–70. [Gubar E.E., Korsakova Yu.L., Loginova E.Yu., et al. Nail lesions in psoriatic arthritis. Data from the All-Russian registry. Nauchno-prakticheskaya revmatologiya=Scientific and Practical Rheumatology. 2021;59(5);563–70. (In Russ.)].
  9. Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А. и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности воспалительного процесса, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Альманах клинической медицины. 2018;46(5);426–44. [Abdulganieva D.I., Bakulev A.L., Belousova E.A., et al. Draft interdisciplinary guidelines for diagnostics, methods for assessing the degree of activity of the inflammatory process, therapeutic efficacy, and the use of genetically engineered biological drugs in patients with combined immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn’s disease). Al’manakh klinicheskoy meditsiny. 2018;46(5);426–44. (In Russ.)].
  10. Dogra S., Mahajan R. Biologics in pediatric psoriasis – efficacy and safety. Expert Opin Drug Saf. 2018;17(1):9–16. https://dx.doi.org/10.1080/14740338.2018.1391787
  11. Жукова О.В., Артемьева С.И., Аль-Хаватми А.A.-Х.M. Псориаз ногтей: динамика клинического течения на фоне терапии препаратами ИЛ-17. Медицинский совет. 2022;16(3):38–45. [Zhukova O.V., Artemyeva S.I., Al-Hawatmi A.A.-H.M. Nail psoriasis: clinical course dynamics during therapy with IL-17 preparations. Meditsinskiy sovet=Medical Council. 2022; 16(3):38–45. (In Russ.)].
  12. Gottlieb A.B., Mease P., McInnes I.B., et al. Secukinumab, a human anti-interleukin-17a monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial. Arthrit Rheumatol. 2014;66:233.
  13. Круглова Л.С., Хотко А.А. Опыт применения секукинумаба при различных формах псориаза в Краснодарском крае. Лечащий врач. 2018;11:7–10. [Kruglova L.S., Khotko A.A. Experience with secukinumab in various forms of psoriasis in Krasnodar Krai. Lechashchiy vrach. 2018;11:7–10. (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).